Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Paresh Vyas et al.|Blood|2018Cited by 1k
Factors predisposing women to chronic pelvic pain: systematic reviewPallavi Latthe, Khalid S. Khan, Luciano Mignini et al.|BMJ|2006Cited by 577
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet StudyDaniela Cilloni, David Grimwade, Aline Renneville et al.|Journal of Clinical Oncology|2009Cited by 434
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 TrialAlan K. Burnett, Donald Milligan, Nigel H. Russell et al.|Journal of Clinical Oncology|2013Cited by 415
Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12Christine J. Harrison, Brenda Gibson, Robert K. Hills et al.|Journal of Clinical Oncology|2010Cited by 305